Saskia Hell
YOU?
Author Swipe
View article: Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma Open
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with respon…
View article: Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma Open
B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with respon…
View article: P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION Open
Topic: 22. Stem cell transplantation - Clinical Background: Allogeneic hematopoietic stem cell transplantion (allo-HSCT) is considered standard of care in eligible patients (pts) with acute myeloid leukemia (AML) and intermediate or advers…
View article: STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT
STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT Open
Background: High-dose therapy followed by autologous stem cell transplantation (ASCT) is the standard first line treatment for younger patients (<70 years) with multiple myeloma (MM). Approximately 20%–50% of all patients already display a…
View article: Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma Open
Markers predicting response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected cells isolated from peripheral blood and bone marrow before and after the app…
View article: P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS Open
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is still the only potentially curative treatment for patients (pts) with high-risk acute myeloid leukemia (AML). Despite recent advances, a significant number of pts are…
View article: Controversies on the Consequences of Iron Overload and Chelation in MDS
Controversies on the Consequences of Iron Overload and Chelation in MDS Open
Many patients with MDS are prone to develop systemic and tissue iron overload in part as a consequence of disease‐immanent ineffective erythropoiesis. However, chronic red blood cell transfusions, which are part of the supportive care regi…